Clinical Trial

Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder

Name: Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder — clinical trial record (NCT07102524)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SLC13A5

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

Phase 1/2, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of TSHA-105 in individuals with SLC13A5 Citrate Transporter Disorder

Protocol Amendment History 2 changes

critical Recruitment opened 2026-07-01

notable Enrollment increased: 2 -> 8 participants 2026-06-18

Trial Details

NCT Number	NCT07102524
Lead Sponsor	TESS Research Foundation
Conditions	SLC13A5 Citrate Transporter Disorder
Enrollment	8 participants
Start Date	2026-07-15
Primary Completion	2030-12-01 (estimated)
Study Completion	2031-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-30